semaj83/ctmatch_classification huggingface dataset:
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 11.0-14.0,  Adolescent Development Stress Emotional Disturbances Female, 11 to 14 years of age Meet Tanner developmental stage (as indicated by self-report and pictorial scales of breast and pubic hair development) for pubertal stages 3 or 4 Must be undergoing a healthy pubertal transition, pre-or-post menarche (within 15 months of menarche, with cycle irregularity) Girls must be able to read at a 4th-grade reading level  Current suicidal intent (based off Columbia-Suicide Severity rating scale) A history or current diagnosis of bipolar disorder or psychosis Currently on any prescription medications
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 6.0-40.0,  Turner Syndrome Children, adolescents, and adult women with Turner syndrome Healthy controls Normal or corrected to normal vision  Major psychiatric or developmental disorder (e.g., bipolar disorder, major depression, psychotic disorders, intellectual disability, autism spectrum disorder) Chemical dependency Currently taking the following medications: antidepressant, antipsychotic, and anti-seizures drugs
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Von Willebrand Disease Historically lowest VWF:Ag and/or VWF:RCo and/or VWF:CB ≤ 0.30 IU/mL and/or FVIII:C ≤ 0.40 IU/mL Treatment at a Hemophilia treatment center in the Netherlands All types of VWD All ages  Other known bleeding disorders present
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hereditary Hemorrhagic Telangiectasia Dental Diseases patients having telangiectasia and nosebleeds or nosebleeds in the family
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-3.0,  Seizures Development Delay Anesthetic Neurotoxicity Male or female aged 0-36 months who received anesthesia (volatile gas anesthesia) or IV sedation (propofol, dexmedetomidine, barbiturates, benzodiazepines, or other agents) for brain MRI  MRI without sedation, brain MRI plus additional MRI imaging, i.e. spine, heart, etc., sedated MRI by a member of other department besides Anesthesiology
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 14.0-49.0,  Hemolytic-Uremic Syndrome Patients will be included if admitted to the ICU with a diagnosis of hypertensive disorder associated with pregnancy and/or sepsis, and meet the following for pregnancy related thrombotic microangiopathy  Non-pregnant women
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hyperventilation Syndrome Hypocapnia Alkalosis, Respiratory Hyperventilation The patient must have reached the age of the civil majority (≥ 18 yo) 2. All patients refered to the Physiology department of Rouen University Hospital, France, for an hyperventilation test 3. The patient must be a member or beneficiary of a health insurance program 4. The patient must have given his / her free and informed consent and signed the consent  Sepsis 2. Hypercapnia (PaCO2 > 50mmHg) 3. Patient treated by long-term oxygen therapy 4. Subjects under judicial protection, or adults under any kind of guardianship or under judicial control 5. Pregnancy or breastfeeding women 6. Electrolytic unbalance 7. Hyperthyroidism 8. Neurological disease 9. Probability of drug-induced hyperventilation (progestagens , aspirin, beta agonists)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 10.0-17.0,  Cerebral Palsy Central Nervous System Diseases Brain Damage, Chronic Diagnosis of bilateral spastic Cerebral Palsy (CP) Age 10 to 17 years inclusive GMFCS levels I, II, or III  Orthopedic or neurosurgery less than 12 months prior to enrollment Injection therapies (phenol, botulinum toxin) less than 3 months prior to enrollment Lacking greater than 25 degrees of knee extension
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Growth Hormone Deficiency in Children Children/adolescents, male or female, aged 8 to 18 years who self-inject GH as well as their parents/legal guardians or Parents/Legal guardians who administer GH to a child/adolescent, male or female, from birth to 18 years The child/adolescent is on prescribed daily GHT due to idiopathic growth hormone deficiency (GHD), multiple pituitary hormone deficiency (MPHD/organic GHD), small for gestational age (SGA) or Turner syndrome (TS) for at least 6 months before screening visit Signed informed consent obtained by parent/legal guardian and child/adolescent before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)  Mental incapacity, unwillingness or language barrier of participant precluding adequate understanding or cooperation - Previous participation of participant in this study. Participation is defined as having given informed consent in this study Treatment of child/adolescent with any investigational drug within 30 days prior to enrolment into the study
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vasoplegic Syndrome Any patient for whom we are able to obtain consent ahead of their procedure Patients presenting for a procedure in which cardiopulmonary bypass will be required Considered high risk for vasoplegic syndrome Has no contraindications to arterial line or PA catheter placement Develops high-dose vasopressors for 30 min or longer and refractory hypotension consistent with vasoplegic syndrome within 24 hours of coming off cardiopulmonary bypass  Age<18 years Known pregnancy or patients without a documented pregnancy test if not menopausal Known prior anaphylactic or allergic reaction to B12a CKD stage 4 or worse ECMO (extracorporeal membrane oxygenation) prior to study consent Patients currently on cardiopulmonary bypass
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 7.0-16.0,  Turner Syndrome Isolated Growth Hormone Deficiency Cognitive Functions Social Cognition Pediatrics Turner syndrome group  girls with diagnosed Turner syndrome. Isolated GHD group  girls with diagnosed isolated growth hormone deficiency All participants  age between 7 years to 16 years and 11 months informed consent signed by the participant and her parents (or her legal representatives) being registered in the national social security system   Turner syndrome group  patients with chronic pathology other than Turner syndrome karyotype : part of a Y chromosome and r(X) cases medical treatment other than those usually prescribed in patients with Turner syndrome. Isolated GHD group  patients with chronic pathology other than isolated growth hormone deficiency medical treatment other than those usually prescribed in patients with isolated growth hormone deficiency. All participants  diagnosed intellectual disability (IQ<70) or intellectual giftedness history of acquired brain injury sensory disturbances (auditory or visual) incompatible with the achievement of neuropsychological tasks insufficient French language proficiency
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  To Investigate the Characteristics and Prognostic Factors of T. Marneffei Infections and the Causes of Misdiagnosis To Study the Recurrence Indicators and Establish a Therapeutic Effect Evaluation System of T. Marneffei Infections Eligible patients were HIV-negative adults who had talaromycosis that was confirmed by either microscopy or culture  patients were HIV-infected adults who had talaromycosis that was confirmed by either microscopy or culture
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 21.0-56.0,  Infertility,Male Vitamin D Deficiency Male with diagnosis of infertility  Azoospermia
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 3.0-18.0,  Childhood Rhabdomyosarcoma Patients must be ≥ 3 and ≤ 18 years of age The predicted survival period is more than 3 months According to version 1.1, there is at least one measurable lesion Postoperative pathological stage was group II-IV Patients have not received radiotherapy before, and can accept chemotherapy and surgical treatment No other anticancer therapy should be used during radiotherapy The main organs are functioning normally, which meets the following 1. Blood routine examination standards should be met: (no blood transfusion within 14 days) A.HB>90g/L; B.ANC>1.5*109/L; C.PLT>80*109/L 2. Biochemical tests should meet the following A. BIL < 1.25 times normal upper limit (ULN); B. ALT and AST < 2.5 ULN; C. Serum Cr < 1 ULN, endogenous creatinine clearance > 50 ml/min Subjects volunteered to participate in this study, patients or legal guardians signed informed consent through patient consent, good compliance, with follow-up Doctors believe that treatment can benefit patients
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-100.0,  Tuberculosis Pediatric ALL Behavior, Health Caretakers of a child who is 1) < 5 years old 2) contact of a TB patient 3) has an IPT prescription from the TB physician and 4) has a smartphone that can use WhatsApp to receive the intervention  Caretaker does not want to participate or cannot provide consent
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 10.0-13.0,  Adolescent Behavior Gender girls and boys 10-13 at time of enrollment in Act With Her Arms girls 11-13 female at time of enrollment in Her Spaces Arm  None
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.167-80.0,  Neurodevelopmental Regression, Seizures, Autism and Developmental Delay (NEDAMSS) Autism Spectrum Disorder Movement Disorders Seizures Dystonia Living or deceased individuals with variants in the IRF2BPL gene  None
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Richter Syndrome Entry for randomised trial component (standard of care and experimental arms): for the randomised trial component Suitable for anthracycline-containing chemo-immunotherapy Patients with CLL and newly diagnosed biopsy proven DLBCL-type RS ECOG performance status of 0, 1, 2 or 3 Age 16 years and over Signed written informed consent prior to performing any study-specific procedures  for the randomised trial component Prior therapy with CHOP or any anthracycline containing treatment at any time prior to randomisation. (Please note that pre-treatment with prednisolone up to 2mg/kg is allowed for up to 14 days prior to the start of treatment) Ibrutinib-exposed CLL patients who have been newly diagnosed with RS within four weeks of their last dose of ibrutinib. (Ibrutinib-exposed CLL patients who discontinue ibrutinib due to toxicity or progressive CLL and later (more than four weeks) develop RS are not excluded from the randomised trial component) Previous acalabrutinib exposure. (Prior exposure to other Bruton tyrosine kinase (BTK), phosphoinositide-3-kinase (PI3K), or BCL-2 inhibitors is permitted, with the exception of patients who have progressed on ibrutinib see criterion above) Known central nervous system (CNS) involvement of CLL or DLBCL Any other active malignancy that requires active treatment, with the exception of basal cell carcinoma, in-situ cervical cancer, and non-invasive squamous cell carcinoma of the skin Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, and active hepatitis Positive serology for Hepatitis B (HB) defined as a positive test for HB surface antigen (HBsAg). In addition, if negative for HBsAg but HB core antibody (HBcAb) positive (regardless of HBsAb status), a HBV deoxyribonucleic acid (DNA) test will be performed and if positive the patient will be excluded Known human immunodeficiency virus (HIV) positive
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 3.0-12.0,  Venipuncture outpatients scheduled to venipuncture Italian speaking  cognitive and/or developmental impairment
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Thyroid Cardiac Remodeling, Ventricular STEMI with a confirmed STEMI diagnosis undergoing primary percutaneous coronary intervention (presenting <12h after symptom onset) patients agreed and provided informed consent  past history of myocardial infarction or percutaneous coronary intervention or coronary artery bypass graft past history of heart failure (LVEF<40%) or myocardiopathy or atrial fibrillation past history of thyroid diseases, or were treated with amiodarone, dopamine, or corticosteroids before hospital admission contraindicating to cardiac magnetic resonance imaging